Results 141 to 150 of about 3,771,587 (392)

Integrin-linked kinase (ILK): the known vs. the unknown and perspectives [PDF]

, 2022
Agata Górska, Antonina Joanna Mazur
openalex   +1 more source

Role of AMP-activated protein kinase in mechanism of metformin action.

Journal of Clinical Investigation, 2001
Gaochao Zhou, R. W. Myers, Ying Li, Yuli Chen, Xiaolan Shen, J. Fenyk-Melody, Margaret S. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. Hirshman, L. Goodyear, D. Moller   +13 more
semanticscholar   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

MO046NON-ACTIVATABLE MUTANT OF INHIBITOR OF KAPPA B KINASE α (IKKα) EXERTS SITE-SPECIFIC EFFECTS ON ATHEROSCLEROSIS [PDF]

, 2016
Pathricia V. Tilstam, Wendy Theelen, Setareh Alampour-Sarabi, Lukas Pawig, Yaw Asare, Yvonne Döring, Menno P.J. de Winther, Toby Lawrence, Alma Zernecke, Jürgen Bernhagen, Andreas Schober, Joachim Jankowski, Christian Weber, Heidi Noels   +13 more
openalex   +1 more source

Supplementary Figure Legends from Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk <i>TP53</i> Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence

, 2023
Abdullah A. Osman, Marcus M. Monroe, Marcus V. Ortega Alves, Ameeta A. Patel, Panagiotis Katsonis, Alison L. Fitzgerald, David M. Neskey, Mitchell J. Frederick, Sang Hyeok Woo, Carlos Caulı́n, Teng‐Kuei Hsu, Thomas O. McDonald, Marek Kimmel, Raymond E. Meyn, Olivier Lichtarge, Jeffrey N. Myers   +15 more
openalex   +1 more source

Self-assembly of an anion receptor with metal-dependent kinase inhibition and potent in vitro anti-cancer properties [PDF]

, 2021
Simon J. Allison, Jarosław Bryk, Christopher J. Clemett, Robert A. Faulkner, Michael L. Ginger, Hollie B. S. Griffiths, Jane Harmer, P. Jane Owen‐Lynch, Emma Pinder, Heiko Wurdak, Roger M. Phillips, Craig R. Rice   +11 more
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors [PDF]

, 2022
Gabrielle Leclercq-Cohen, Nathalie Steinhoff, Hélène Haegel, Donata De Marco, Marina Bacac, Christian Klein   +5 more
openalex   +1 more source

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk

Frontiers in Neurology, 2022
Robert K. Lesniak, Robert K. Lesniak, R. Jeremy Nichols, Thomas J. Montine   +3 more
doaj   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source